Premium
Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study
Author(s) -
VAN ZAANE B.,
SQUIZZATO A.,
DEBEIJ J.,
DEKKERS O. M.,
MEIJERS J. C. M.,
VAN ZANTEN A. P.,
BÜLLER H. R.,
GERDES V. E. A.,
CANNEGIETER S. C.,
BRANDJES D. P. M.
Publication year - 2011
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2011.04430.x
Subject(s) - fibrinolysis , levothyroxine , medicine , coagulation , endocrinology , thromboelastography , plasminogen activator , partial thromboplastin time , crossover study , von willebrand factor , fibrinogen , plasminogen activator inhibitor 1 , hemostasis , hormone , placebo , platelet , alternative medicine , pathology
Summary. Background: Several hemostatic abnormalities have been reported in hyperthyroidism, but the overall effect of thyroid hormone excess on coagulation and fibrinolysis is unclear. Objective: Our aim was to assess whether the use of supraphysiological doses of levothyroxine leads to coagulation activation and inhibition of fibrinolysis. Patients and methods: Healthy volunteers were randomized to receive levothyroxine or no medication for 14 days with a washout period of at least 28 days in a crossover design. To study the effects of different degrees of thyroid hormone excess, 16 participants received levothyroxine in a dose of 0.3 mg per day, and 12 received levothyroxine 0.45 or 0.6 mg per day depending on body weight. Several variables of coagulation and fibrinolysis were measured. Results: Levels of von Willebrand factor activity (VWF:RiCo) and antigen (VWF:Ag), factor (F) VIII, plasminogen activator inhibitor‐1 (PAI‐1) and clot‐lysis time were slightly higher after levothyroxine 0.3 mg per day than after the control situation, but only levels of VWF showed a significant increase from baseline. After levothyroxine 0.45 or 0.6 mg per day, levels of fibrinogen increased by 17%, VWF activity by 24%, VWF antigen by 26%, FVIII by 19%, FIX by 14%, FX by 7%, PAI‐1 by 116% and clot‐lysis time by 14%, and activated partial thromboplastin time decreased by 3%; all were significant changes compared with the control situation. We did not observe clear evidence of coagulation activation. Conclusions: Our data suggest that thyroid hormone excess increases coagulation factor levels and inhibits fibrinolysis in a dose‐dependent fashion. This implies an increased risk of venous thrombosis during hyperthyroidism.